Can I Take St. John's Wort with Provigil (Modafinil)?

What Is the Interaction Between St. John's Wort and Modafinil?

St. John's Wort (Hypericum perforatum) reduces modafinil plasma concentrations by inducing CYP3A4, the liver enzyme that partially metabolizes modafinil. Lower blood levels mean the drug may no longer keep you awake at the prescribed dose, potentially triggering the exact sleepiness it was meant to prevent. This is a pharmacokinetic interaction, not a pharmacodynamic one, so you are unlikely to feel a dramatic sudden change. The effect builds gradually over days.

How CYP3A4 Induction Works

Cytochrome P450 3A4 is responsible for metabolizing roughly 50% of all marketed drugs [1]. Enzyme inducers like St. John's Wort increase the amount of CYP3A4 protein produced in liver and intestinal cells, causing faster drug breakdown and lower systemic exposure.

The active inducers in St. John's Wort are hyperforin (primarily) and to a lesser extent hypericin. Hyperforin activates the pregnane X receptor (PXR), a nuclear receptor that directly upregulates CYP3A4 gene transcription [2]. This process is not immediate. Enzyme induction typically begins within 3 to 7 days of starting St. John's Wort and reaches its peak effect around 10 to 14 days [3].

Where Modafinil Fits in CYP3A4 Metabolism

Modafinil is both a substrate and a mild inducer of CYP3A4 at steady state. The Provigil prescribing information notes that modafinil itself can reduce exposure to co-administered CYP3A4 substrates such as cyclosporine and oral contraceptives by approximately 40 to 50% [4]. Adding a potent external CYP3A4 inducer like St. John's Wort on top of that creates a bidirectional metabolic pressure: the supplement accelerates modafinil clearance, while modafinil simultaneously reduces the levels of other drugs in your regimen.

Clinical Evidence for the St. John's Wort-CYP3A4 Effect

A 2004 crossover pharmacokinetic study (N=12 healthy volunteers) by Wang et al. Found that 14 days of St. John's Wort 300 mg three times daily reduced the area under the curve (AUC) of alprazolam, a CYP3A4 substrate, by 54% (P<0.001) [5]. While a direct modafinil-St. John's Wort pharmacokinetic trial has not been published, the principle is mechanistically identical. The FDA-approved Provigil label explicitly lists "inducers of CYP3A4" as agents that may decrease modafinil exposure [4].

A controlled interaction study by Markowitz et al. (2003, N=16) confirmed St. John's Wort's ability to reduce plasma levels of indinavir, another CYP3A4 substrate, by 57% after 14 days of co-administration [6]. Reductions of this magnitude in a wakefulness-promoting agent would translate clinically to treatment failure for narcolepsy or shift work sleep disorder.

The Contraceptive Failure Risk: A Second Layer of Concern

This is perhaps the most underappreciated clinical risk of combining St. John's Wort with modafinil.

How Two CYP3A4 Inducers Stack

Modafinil alone induces CYP3A4 sufficiently to reduce plasma ethinyl estradiol (the estrogen component of most oral contraceptives) by approximately 18% at steady state, according to a Cephalon-sponsored pharmacokinetic study cited in the original FDA labeling [4]. St. John's Wort independently reduces ethinyl estradiol AUC by 10 to 30% in published interaction studies [7].

When both are taken together, these inductive effects are additive and potentially synergistic at the enzyme level. A person relying on a combined oral contraceptive for pregnancy prevention could face substantially reduced steroid exposure, increasing ovulation risk.

FDA and Guideline Warnings

The Provigil FDA label states directly: "The effectiveness of steroidal contraceptives may be reduced when used with Provigil and for one month after discontinuation of Provigil. Alternative or concomitant methods of contraception are recommended" [4].

The Faculty of Sexual and Reproductive Healthcare (FSRH) in the United Kingdom similarly advises that both St. John's Wort and modafinil are enzyme inducers that compromise combined hormonal contraception [8]. Anyone taking modafinil with St. John's Wort should use a barrier method in addition to any hormonal contraceptive for the duration of use and for at least four weeks after stopping either agent.

Practical Risk Stratification

The table below organizes risk by patient type.

| Patient Profile | Primary Risk | Recommended Action | |---|---|---| | Taking modafinil alone for narcolepsy | Loss of wakefulness efficacy | Avoid St. John's Wort; discuss alternatives with prescriber | | Taking modafinil plus oral contraceptive | Contraceptive failure + reduced modafinil efficacy | Avoid St. John's Wort; use barrier backup; prescriber review | | Taking modafinil for shift work off-label | Reduced drug exposure at fixed dose | Do not self-supplement; review with prescriber | | Considering St. John's Wort for depression on modafinil | Reduced antidepressant and wakefulness effect | Prescriber should evaluate SSRI/SNRI alternatives |

Pharmacodynamic Considerations: Can Both Affect the Brain Separately?

Beyond enzyme induction, it is worth asking whether St. John's Wort and modafinil interact at the receptor level.

Modafinil's Mechanism

Modafinil promotes wakefulness primarily through dopamine transporter (DAT) inhibition, elevating synaptic dopamine in the hypothalamus and prefrontal cortex. It also modestly increases norepinephrine, histamine, and orexin signaling [9]. At therapeutic doses of 200 to 400 mg, it does not significantly inhibit serotonin reuptake.

St. John's Wort's Mechanism

Hyperforin is a reuptake inhibitor of serotonin, dopamine, norepinephrine, GABA, and glutamate simultaneously. This broad monoamine activity is why St. John's Wort has demonstrated efficacy comparable to low-dose sertraline in mild-to-moderate depression. A Cochrane review of 29 trials (N=5,489) found St. John's Wort superior to placebo and similarly effective to standard antidepressants for mild-to-moderate depression, with fewer side effects [10].

Serotonin Syndrome: A Theoretical but Real Concern

Because both modafinil (via dopamine/norepinephrine pathways) and St. John's Wort (via broad monoamine inhibition) alter central monoamine tone, there is a theoretical risk of serotonin excess symptoms when combined, particularly in patients already on an SSRI or SNRI. Serotonin syndrome can present as agitation, tremor, hyperthermia, and tachycardia. The risk from modafinil plus St. John's Wort alone is low, but it rises steeply if a third serotonergic agent is added.

What the Provigil Prescribing Information Says About Drug Interactions

The current FDA-approved labeling for Provigil (modafinil) 100 mg and 200 mg tablets dedicates a specific subsection to CYP3A4 inducers [4]. The label notes that drugs or substances that induce CYP3A4 activity "would be expected to decrease the systemic exposure of modafinil." It lists carbamazepine (Tegretol), phenobarbital, rifampin, and phenytoin as examples of clinical concern. St. John's Wort is not listed by name in the Provigil label, but the FDA has published a separate drug interaction guidance specifically warning that St. John's Wort is a potent CYP3A4 inducer whose clinical effects on substrate drug exposure are well-established [11].

The American Association of Clinical Endocrinology (AACE) and American College of Clinical Pharmacy both recommend asking patients about supplement use at every visit precisely because herb-drug pharmacokinetic interactions of this type are routinely missed in clinical settings.

How Long Does the Interaction Last After Stopping St. John's Wort?

Enzyme induction is not reversible overnight.

Washout Timeline

CYP3A4 induction from St. John's Wort persists until the induced enzyme protein degrades to baseline. The half-life of CYP3A4 protein turnover is approximately 23 to 38 hours, but functional enzyme activity typically takes 10 to 14 days to return to pre-induction levels after stopping the supplement [3]. This means:

• You should wait at least 14 days after your last dose of St. John's Wort before expecting your prescribed modafinil dose to achieve its normal plasma exposure.
• During that washout window, narcolepsy patients may experience breakthrough sleepiness despite taking their usual modafinil dose. Your prescriber may need to adjust dosing temporarily.

Dose Adjustment Is Not a Simple Fix

Some clinicians consider increasing the modafinil dose to compensate for induction. The maximum approved dose is 400 mg/day for narcolepsy and obstructive sleep apnea [4]. Dose escalation beyond this threshold is off-label and carries higher risks of insomnia, anxiety, headache, and cardiovascular strain. The cleaner solution is to discontinue St. John's Wort, wait the full 14-day washout, and reassess.

What If You Are Already Taking Both?

Do not stop either agent abruptly without medical advice.

Immediate Steps

1. Tell your prescriber or pharmacist you are taking both. Be specific about the St. John's Wort dose and brand, because hyperforin content varies substantially between products.
2. Ask your prescriber whether your current modafinil dose is likely subtherapeutic. Symptoms of inadequate modafinil effect include return of daytime sleepiness, difficulty staying awake during work or driving, and increased sleep attacks in narcolepsy.
3. If you are also using hormonal contraception, switch to a barrier method immediately and continue it for at least four weeks after stopping both the supplement and modafinil, or discuss longer-acting non-hormonal contraception with your gynecologist.

Monitoring Parameters

Your prescriber may order a clinical assessment of sleepiness using the Epworth Sleepiness Scale (ESS), a validated eight-item questionnaire where a score above 10 suggests excessive daytime sleepiness requiring attention [9]. Blood levels of modafinil are not routinely measured in clinical practice, but the ESS provides an indirect functional marker of drug exposure.

Are There Safer Supplements to Take Alongside Modafinil?

Patients often turn to St. John's Wort because they are managing low mood or fatigue alongside their primary sleep disorder. Reasonable alternatives with lower interaction potential include:

• Vitamin D3: Low vitamin D is associated with fatigue and mood changes. Supplementation at 1,000 to 2,000 IU/day carries minimal CYP3A4 interaction risk.
• Magnesium glycinate: Commonly used for sleep quality. No significant CYP3A4 interaction with modafinil is documented.
• Omega-3 fatty acids (EPA/DHA): A meta-analysis in JAMA Network Open (2019, N=19 trials) found omega-3 supplementation significantly reduced depressive symptoms (SMD 0.26, P<0.001), with no known enzyme-induction concerns [12].

These options should still be disclosed to your prescriber, but they do not carry the CYP3A4 interaction risk that makes St. John's Wort problematic with Provigil.

Key Takeaways for Patients and Clinicians

St. John's Wort and modafinil should not be taken together as a routine practice. The combination reduces modafinil plasma exposure through CYP3A4 induction, compounds contraceptive failure risk when hormonal birth control is present, and introduces theoretical serotonergic additive effects. The FDA Provigil label identifies CYP3A4 inducers as agents that reduce modafinil efficacy, and published pharmacokinetic studies confirm that St. John's Wort reduces the AUC of CYP3A4 substrates by 50 to 57% after 14 days of co-administration. If you are currently taking both, inform your prescriber today, switch to barrier contraception if applicable, and plan a supervised 14-day washout of St. John's Wort before reassessing your modafinil dose.